Phaseline

Targets › CYP24A1

CYP24A1 (1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Dec 2027.

A cytochrome P450 monooxygenase with a key role in vitamin D catabolism and calcium homeostasis. Via C24- and C23-oxidation pathways, catalyzes the inactivation of both the vitamin D precursor calcidiol (25-hydroxyvitamin D(3)) and the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)). (UniProt, Q07973)

Open in Phaseline: the race on CYP24A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Children's Hospital of PhiladelphiaRifampin
Bacterial DNA-directed RNA polymerase inhibitor
CYP24A1Phase 2Idiopathic Infantile Hypercalcaemia - Severe FormDec 2027

Conditions

Idiopathic Infantile Hypercalcaemia - Severe Form (1)

Modalities

small molecule (1)

Companies

Children's Hospital of Philadelphia (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.